Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Retained Earnings (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Retained Earnings data on record, last reported at -$1.1 billion in Q4 2025.

  • For Q4 2025, Retained Earnings fell 1.44% year-over-year to -$1.1 billion; the TTM value through Dec 2025 reached -$1.1 billion, down 1.44%, while the annual FY2025 figure was -$1.1 billion, 1.44% down from the prior year.
  • Retained Earnings reached -$1.1 billion in Q4 2025 per ARQT's latest filing, down from -$62000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $533000.0 in Q3 2024 and bottomed at -$1.2 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$370.7 million, with a median of -$833000.0 recorded in 2022.
  • The widest YoY moves for Retained Earnings: up 389.67% in 2024, down 28048675.0% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$255000.0 in 2021, then tumbled by 282174.51% to -$719.8 million in 2022, then soared by 100.0% to $4000.0 in 2023, then tumbled by 28048675.0% to -$1.1 billion in 2024, then decreased by 1.44% to -$1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.1 billion in Q4 2025, -$62000.0 in Q3 2025, and -$1.2 billion in Q2 2025.